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ABSTRACT

IMPORTANCE: Age-related macular degeneration (AMD) is a leading cause of low
vision in elderly population. The association of vascular and renal conditions has been
reported inconsistently. Unfolding the association may provide the insight to eye care
providers to take account general health management into eye care.
OBJECTIVES: To investigate the prevalence of the vascular and renal comorbidities
with AMD, examine the association of a single or combination of these comorbidities
with AMD.
DSIGN AND PARTICIPANTS: Population-base cross-sectional study involved the
adults aged 40 years or older (N=4596) who participated in the 2005 to 2008 National
Health and Nutrition Examination Survey (NHANES), a national representative
population-based survey of non-institutionalized US residents.
MAIN OUTCOMES AND MEASURES: AMD was defined by the presence of drusen
and presence of pigmental abnormality. Angina pectoris (AP), coronary heart disease
(CHD), congestive heart failure (CHF) and myocardial infarction (MI), and stroke,
assessed by self-report by the questionnaire of medical conditions, Chronic kidney
disease (CKD), assessed by self-report and estimation of glomerular filtration rate (GFR)
and the level of urine albumin. Heart disease (HD) was defined as having AP or CHF or
CHD or MI.
RESULTS: Among individuals with AMD, 6% had AP, 10% had CHD, 7% had CHF,
10% had MI, 13% had stroke, and 29% had CKD. The weighted prevalence of these
conditions were significantly higher than those without AMD (All P-values <0.05). The
4

estimated crude odds ratios (ORs) for the association between a single comorbidity and
AMD were the following: 1.96 (95%CI: 1.24-3.10) for AP; 2.46 (95%CI, 1.67-3.64) for
CHD, 2.38 (95% CI, 1.64-3.45) for MI, 2.51 (95% CI, 1.60-3.95) CHF, 2.59 (95% CI,
1.95-3.43) HD, 3.91( 95%CI, 2.72-4.36) for stroke, and 3.35 (95% CI, 2.57-4.36) for
CKD. Adjusting for gender, age and other risk factors, ORs were attenuated but
remained elevated and statistically significant; whereas, AP was no long significantly
associated with AMD. One of three comorbidities (HD, Stroke and CKD) ( Crude OR:
2.78 (95%CI: 2.00-3.78); adjusted OR: 2.60 (95% CI: 1.71-3.92)), combination of the
comorbidities (Crude OR: 3.93 (95%CI: 2.69-5.73); adjusted OR: 2.33 (95%CI: 2.733.99)) were associated with AMD. The association of the combination of CKD and
Stroke was the strongest (Crude OR: 7.43 (95%CI: 4.51-12.27); adjusted OR: 5.50
(95% CI: 2.74-12.02)).
CONCLUSION AND RELEVANCE: These findings from the nationally-representative
sample of the US population highlight the prevalence of vascular and renal
comorbidities associated with AMD, the modest evidence of relationship of each single
comorbidity, and strong association of combination of stroke and CKD to AMD
independent of age, gender, and other factors. Because of the cross-sectional design,
the results of this study can not address a causal relationship between AMD and the
examined comorbidities. It is unclear whether AMD and comorbidities arise from
individual predisposition to vascular and renal diseases or whether complications from
these morbidities increase the risk of AMD. However, the important caveat is that
preventive and care management for the examined comorbidities may lessen the
severity of symptoms or prevent AMD.
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CHAPTER I
INSTRUCTION
Age-related macular degeneration (AMD) is one of most common ocular
diseases in the elderly population. The prevalence of AMD is reported as 9.8% among
people aged 65 years or older, while 6.5% in individuals aged 40 years or older in US
population (Klein et al., 2011; Klein et al., 2010). Although the prevalence of AMD
decreases from 9.4% to 6.5% in US population aged 40 years or older during the last
decade (Klein, et al., 2011; Klein et al., 1999), it is still a contributable cause of visual
impairment and blindness (Chou et al., 2013; Foran, Wang, & Mitchell, 2003), which
significantly impact on individual health quality of life, and increase severity of public
health concern. Gaining population-based evidence of AMD is significant for lowing the
incidence of AMD and blindness since the effective treatment and clinical management
of AMD remains challenge (van Lookeren Campagne, LeCouter, Yaspan, & Ye, 2014).

Concurrence of medical conditions is more prevalent with age, one of four
Americans has two or more conditions age more than 40 years. AMD, a multifactoral
disease, is more likely coexisting with the diseases which share common risk factors or
biological plausible pathways. The substantial presence of the associated comorbidities
of AMD could resulted in an increased frequency of disability of vision impairment and
overall burden of diseases to our society. Study on the association between these
comorbidities and AMD would predict the outcomes of AMD and provide the insight for
eye care management so as to reduce the worse outcome.
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Heart diseases, stroke and chronic kidney disease (CKD ) are major vascular
diseases, and each of them shares common risk factors of AMD. The linkage between
these conditions and AMD has been reported, but the results were inconsistent. A study
has reported that AMD may be the risk predictor of coronary heart disease (CHD)
relating to high mortality (Tan, Wang, Liew, Rochtchina, & Mitchell, 2008), by contrast,
another study has showed that AMD is not associated with CVD and CHD (Fernandez
et al., 2012). The AMD was associated with stroke (Tan, et al., 2008), but not
associated with cerebral infarction (Wieberdink et al., 2011), moreover, the early AMD is
not a risk factor of stroke in people aged 69 to 97 years (Sun, Klein, & Wong, 2009).
CKD patients are in a higher risk of early AMD (Liew, Mitchell, Wong, Iyengar, & Wang,
2008). With the inconsistency, there is a rationale for an investigation of the relationship
between vascular and renal comorbidities and AMD because the substantial present of
these associated comorbidities would increase overall health burden of AMD in both
individual and society level. The measurement of concurrence between AMD and the
comorbidities will unfold the association by using national representative population, it
will lead to the better visual outcomes of AMD patients, if these comorbidities are taken
account into eye care management.
We conducted a study to investigate whether there is an association between
AMD and vascular and renal conditions including heart disease (HD) containing angina
pectoris (AP), coronary heart disease (CHD), congestive heart failure (CHF) and
myocardial infarction (MI), stroke and chronic kidney disease (CKD). We utilized the
data of 2005 - 2008 National Health and Nutrition Examination Survey (NHANES), a
national representative sample of US population. We compared the prevalence of these
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vascular and renal diseases among individual with AMD to those without AMD. We
analyzed the association between AMD and each vascular and renal medical condition.
We explored the relationship between AMD and combination of three conditions (HD,
Stroke and CKD). We hypothesized that the individuals with these vascular and renal
medical conditions will have an association with AMD, the association with combined
comorbidities may be stronger comparing to the single comorbidity.
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CHAPTER II
REVIEW OF LITERATURE
II.I Age-related Macular Degeneration
Age-related macular degeneration (AMD) is a neurodegenerative ocular disease
affecting the population aged 40 years or older. It is a leading cause of blindness
accounting for up to 50% of all cases of legal blindness in the United States. The typical
lesion of AMD occurs at the retinal macular area. The damage to the macula results in
impairment of central acuity and eventually loss of vision. AMD is categorized in two
stages based on clinical manifestations: early and late AMD. The early AMD is
asymptomatic with the appearance of numerous large drusen in the retina identified by
retinal image. The drusen develop from the slow progressive degeneration of the retinal
pigment epithelium and retinal photoreceptors (Lengyel et al., 2004). Early AMD
accounts for approximately 80% of the reported cases of all AMD. Late AMD is divided
into two types: choroidal neovascularization (CNV, also known as wet AMD) and
geographic atrophy (GA, also known as dry AMD) based on presence or absence of
invasive new blood vessels in the retina (Zweifel, Imamura, Spaide, Fujiwara, & Spaide,
2010). Late AMD accounts for about 20% of all AMD; however, late AMD is responsible
for majority of blindness (Bourne et al., 2013). Several novel treatments for late AMD
have been identified. An intraocular injection of an anti-vascular endothelial growth
factor (VEGF) agent (Akpek & Smith, 2013) is available for treatment of the CNV type of
AMD. These agents have substantially gained the vision back and reduced the risk of
blindness in some but not all patients. In contrast, there is no approved treatments for
GA type of AMD. Effective management of AMD remains a significant challenge. Early
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detection and prevention of AMD, therefore, is important to reduce the incidence of
AMD and improve the quality of vision. Population-based epidemiological studies are
capable of providing the evidence for the etiology of AMD in order to establish of
prevention program of reduction of risk factors of AMD.

II.II Pathogenesis of AMD
AMD is generally considered as a complex genetic disorder influenced by
environmental risk factors. Although biological mechanisms of AMD are largely
unknown, major progress in understanding the pathogenesis of AMD have been made
through the advances of molecular cell biology and genetics in the past decade
implicating several pathogenetic pathways including oxidative damage, chronic
inflammation, and excessive accumulation of lipofuscin, (Whitcup et al., 2013).
Activation of immune cells in the retina, including microglia cells, Muller cells RPE cells
and macrophages related to the pathway of GA type of AMD (Cherepanoff,
McMenamin, Gillies, Kettle, & Sarks, 2010). Complement activation is reported to
associated to the inflammation pathophysiological way of AMD. Molecular pathological
evidence of oxidative damage in the retina linked to immune response has indicated the
relevance of oxidative stress to initiate the development of AMD (Hollyfield et al., 2008).
In addition, it is very accepted that genetic contribution is strongly correlated to the risk
of AMD. Genetic analyses reveal that there is correlation between GA type of AMD risk
and variations in genes encoding negative regulators in complement pathways,
including complement factor H (CFH) and factor I (CFI ), as well as additional
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components of the AP such as complement factors B (CFB) and C3 (Fagerness et al.,
2009; Heurich et al., 2011).

II.III The Epidemiology of AMD
The population of AMD patients bears the greatest burden of health due to
disabilities in vision loss, complications and co-morbidities. Population-based studies on
AMD are vital for understanding the etiology of AMD to reduce the burden of disease.
There have been many epidemiological studies on the prevalence and incidence of
AMD and decreased trend of prevalence of AMD is observed. The Framingham Eye
Study reported the prevalence of AMD among people aged 52-85 years was 8.8%
(Leibowitz et al., 1980). A fifteen year accumulative prevalence of ADM study has
shown the prevalence of early stage of AMD was 24%, late state was 8% among people
aged 75 and older (Klein et al., 2007). The Beaver Dam Offspring study estimated a
9.8% prevalence of AMD among people aged more than 65 years (Klein, et al., 2010).
In the US population aged 40 years and older, the prevalence of any AMD was 6.5%
and the prevalence of late AMD was 0.8% (Klein, et al., 2011). The disparity of
prevalence of AMD among racial/ethnic groups has been observed and the prevalence
of AMD is higher among the whites than any other racial groups. Dr. Klein et al's study
has shown that blacks aged 60 years and older had a lower prevalence of AMD (OR =
0.37; 95% CI, 0.21-0.67) than non-Hispanic white persons in the same age groups
(Klein, et al., 2011). It is thought that the prevalence of AMD does not differ from
gender, although women have higher risk of CNVAMD (OR:1.2; 95% CI: 1.0-1.5 ) in one
study (Owen et al., 2012). The population-based studies have led to major advances in
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the understanding of the risk factors of AMD. A meta-analysis has reported that 73 risk
factors of AMD are associated with AMD, and aging, cigarette smoking, previous
cataract surgery and a family history of AMD are the risk factors consistently
(Chakravarthy et al., 2010). In addition, factors of social economic status, oxidative
stress (Hollyfield, et al., 2008), low level of antioxidants (Chew et al., 2013) and
nutritional factors (Chew, et al., 2013; Wlodarek & Glabska, 2011) have been implicated
as risk factors for the occurrence of AMD. Many of the etiological risk factors of AMD
are commonly shared with medical conditions of different organ systems. Exploring the
relationship between ADM and organ system diseases is ideal for understanding the
etiology of AMD.

II.IV Vascular and Renal Comorbidities and AMD
Comorbidity is widely defined as the presence of more than 2 diseases in an
individual. These conditions could be occurring synchronously or sequentially. For
example, a patient with established depression is diagnosed with a glaucoma differs
from a patient with depression and later is found to have a glaucoma. Comorbidity is
usually associated with a worse outcome, consequently increasing health care cost.
About 80% of health care expenditure in the United States is spent on patients who
have 4 or more chronic diseases (Wolff, Starfield, & Anderson, 2002). Comorbidities
often display either common etiological pathways or biological plausibility, hence the
information of comorbidity predicts not only the disease pathogenesis, prognosis, and
treatment, but also the burden of organ dysfunction. From the point view of
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epidemiology and public health, understanding the comorbidity is very important as
comorbidity is associated with a worse outcome.
Heart disease (HDs) share many common risk factors with AMD suggesting that
HDs may be a comorbidity of AMD. CVDs generates the most health concerns
because of high incidence and prevalence. The estimation from 2007-2010 NHANES
(National Health and Nutrition Examination Survey ), is that one of third deaths was
attributable to CVDs in United States in 2009. One of six deaths is caused by CHD; one
of nine deaths is from congestive heart failure; one of every nineteen deaths is
attributable to stroke; one third of US adults aged 20 years and older have hypertension
(Go et al., 2013). In s population based cohort study in middle-aged persons,
participants with any AMD were at an increased risk of stroke with a stronger
association for intracerebral hemorrhage than cerebral infarction after a mean follow-up
13 years (Ikram et al., 2012). Total serum cholesterol was associated directly with
incident geographic atrophy (Tomany et al., 2004). AMD often coexists with CVD due to
a shared pathogenesis. In this thesis study, common cardiovascular diseases listed in
NHANES dataset are chosen to investigate the epidemiological linkage with AMD .

The association between Coronary heart disease (CHD) and AMD has long been
postulated by epidemiological studies, but the results of the association vary. Several
epidemiological studies have suggested the association between CHD and AMD. The
linkage between the early AMD and an increased risk of CHD (HR1.57; 95% CI, 1.172.22) is described in the Cardiovascular Health Study in the Australian population aged
69-97 (Sun, et al., 2009), Another prospective cohort study has suggested an
association between early AMD and CHD (RR: 1.08; 95% CI 0.82-1.42) in a middle
18

aged Australian population, but the individuals with late AMD had three times higher risk
of incident CHD events (HR= 3.05, 95% CI, 1.14–8.17) (Wong et al., 2007). A case
control study investigating a French population suggested a link between AMD and
CHD (RR: 1.31, 95%CI: 1.02–1.68) (Chaine et al., 1998). Blue Mountains Eye Study
has stated that early AMD had a 2-time increased risk of CHD mortality controls (HR=
2.32, 95% CI, 1.03 to 5.19) (Tan, et al., 2008). On the other hand, the most recent study
has stated that AMD is a not risk indicator of CHD in the Multi-Ethics Study of
Atherosclerosis (HR: 0.99; 95% CI, 0.74-1.33) in the population aged 45 to 84 years
with an over 5.4 year follow-up (Fernandez, et al., 2012). The results implied the
importance for further study of the association between CHD and AMD with a national
representative population.

Heart attack (HA), also known as Myocardial infarction (MI), is one of the most
common cardiovascular diseases and is a consequent of ischemic heart disease
accounting for 12.2% of worldwide deaths based on the estimate of WHO in 2004.
Many risk factors of MI have been postulated in epidemiological studies including age,
smoking, abnormality of blood levels of certain lipids, diabetes, hypertension, and
obesity. Previous cardiovascular disease is the most common risk factor of MI. Angina
Pectoris commonly is thought to be related to myocardial ischemia. Angina also shares
most of the same risk factors with MI. Heart failure also known as congestive heart
failure (CHF) commonly results from cardiovascular diseases including MI. Heart failure
affected 5.8 million people in the United States in 2011. The health care expenditure for
heart failure exceeds $35 billion in the United States due to the hospitalization cost
(Rosamond et al., 2008). The risk factors of CHF includes ischaemic heart disease,
19

hypertension, obesity, and diabetes which are major risk factors for MI and angina
pectoris. Given these same risk factors of angina, MI and CHF with AMD, it is
considerable that there is an association between AMD and angina, MI and CHF.
However, there is no common agreement that this association exists. When reviewing
the evidence from epidemiological studies. There is no association between angina, MI
and AMD in Beaver Dam Eye Study (Klein et al., 2013). MI or angina RR was related
with AMD (HR:1.57; 95% CI: 1.13-2.16) (Tan, et al., 2008), persons with MI was
significantly more prevalent for early AMD (Liutkeviciene et al., 2012), furthermore, MI
was associated with AMD, particularly in neovascular AMD (HR: 1.19; 95%CI: 1.16-1.22)
(Duan et al., 2007). To the contrary, a study using a group of hospitalized
cardiovascular disease patients reported that the rate ratio for MI with neovascular
AMD was protective (HR: 0.58; 95% CI: 0.48-0.72) (Nguyen-Khoa et al., 2008) (Golan
et al., 2011). It is important to investigate the epidemiological relationship between AMD
and angina, MI and CHF with a national population.

Stroke was defined as a "neurological deficit of cerebrovascular cause that
persists beyond 24 hours or is interrupted by death within 24 hours” World Health
Organization, 1978 WHO’s top ten causes of death list stroke as the second most
cause of death worldwide in 2011, accounting for 6.2 million deaths. Risk factors for
stroke that were identified include age, hypertension, previous stroke or transient
ischemic attack (TIA), diabetes, and smoking (Donnan, Fisher, Macleod, & Davis,
2008). High blood pressure is the most important modifiable risk factor of stroke. As a
result, stroke may be linked with AMD. There is no general agreement on this linkage
based on the literature review.
20

The presence of early-stage AMD in persons aged 49 to 73 was associated with
a higher adjusted risk for stroke (HR: 1.87 [95% CI, 1.21- 2.88]) over ten years follow up
(Wong et al., 2006). In a Taiwanese population-based study, neovascular AMD in
patients aged 65 and older was associated with a 2-fold increased incidence of stroke
(Hu, Ho, & Lin, 2010). Moreover, AMD was an indicator of the risk of stroke (HR: 1.51;
95% CI: 1.11-2.06) with an association for both intracerebral hemorrhage (HR: 2.64;
95% CI: 1.18-5.87) and cerebral infarction (HR: 1.42; 95% CI: 1.01-1.99) in the
Atherosclerosis Risk in Communities (ARIC) Study (Ikram, et al., 2012).
In contrary, a retrospective cohort study using hospitalized CVD database found
contradictory results and the rate of cerebrovascular accidents (CVAs) was lower in
neurovascular AMD (RR =0.56, 95% CI, 0.45–0.70) over a 3 year period (Nguyen-Khoa,
et al., 2008). There is no relationship between AMD and Stroke in the Cardiovascular
Health Study (Sun, et al., 2009) and the Beaver Dam Eye Study (Klein, et al., 2013).
Late AMD was associated with an increased risk of any stroke (HR: 1.56; 95% CI: 1.08 2.26), and there was a strong association with intracerebral hemorrhage (HR: 6.11; 95%
CI: 2.34-15.98), but no association with cerebral infarction in the Rotterdam Study
(Wieberdink, et al., 2011). Future studies on AMD as an indicator of the risk of stroke is
important.

Chronic kidney disease (CKD) shares common pathogenetic mechanisms of
AMD including inflammation, oxidative stress, and microvascular dysfunction,
suggesting that CKD may be linked with AMD. A few epidemiological studies of the link
between AMD and CKD have been reported. CKD was associated with AMD (OR, 1.68;
95% CI, 1.04-2.72) (Choi, Moon, & Shin, 2011). Proteinuria and eGFR < 45 ml/min/1.73
21

m were positively associated with AMD only among men (OR2.06, 95% CI 1.05, 4.04)
(Nitsch, Evans, Roderick, Smeeth, & Fletcher, 2009). Mild CKD was associated with the
15 year cumulative incidence of early AMD (OR: 1.36, 95% CI, 1.00-1.86]) in the Beaver
Dam Eye Study (Klein, Knudtson, Lee, & Klein, 2009), the 5-yr incidence of early AMD
with CKD was 4 times higher than those without CKD in the Australian population (Liew,
et al., 2008), and had a higher prevalence of AMD (1.7% vs. 0.9%, P = 0.01) in a
Chinese population-based study (Gao et al., 2011). However, little research of CKD and
AMD with a national population of US has been reported.

This thesis study aims to investigate the association between AMD and vascular
medical conditions including cardiovascular diseases (AP, CHD, MI and CHF), stroke
and CKD.
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CHAPER III
METHODS
III.I Study Population
NHANES is a national representative population-based survey of noninstitutionalized US residents conducted by the National Center for Health Statistics, the
Centers for Disease Control and Prevention (CDC). The subjects, collection and
program description have been published at CDC website. NHANES utilized a complex,
multistage cluster sampling design to achieve the generalizability of US population. In
brief, subjects contain entire non-civilian population in the United States. Data collection
was through a questionnaire survey, medical examination and laboratory tests. Retinal
image photography was conducted 2005 to 2008 and limited to the participants aged 40
years old and older. Data from NHANES 2005 to 2008 were used for this study. Of the
total 20,497 subjects, 6,874individuals were more than 40 years old, and 4,596 (66.9%)
individuals has complete retinal image photography at the time of the completion.
Among the individuals aged more than 40 years, 49.7% were male and 50.4% were
female. To the distribution of racial/ethnicity, non-Hispanic white were 39.2%, nonHispanic black were 24.0%, Mexican American were 24.4%, and other races/ethnicities
were 12.3%. The education distribution shows 54.1% were high school graduate or low,
26.8% indicated some college, 19.1% were college graduate or above.

III.II Sociodemographic and clinical characteristics
Standardized the questionnaires were administered in the home. Physical and
medical lab examinations were conducted in the NHANES examination center by
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trained medical professionals. The demographic, social behavioral and clinical
characteristics were defined for the analysis. Race/Ethnicity was categorized into four
groups: Non-Hispanic Whites, Non-Hispanic Blacks, Mexican American and other race.
Education was defined as high school graduate, College or Associate and College
graduates or more. Family annual incomes were categorized as less than $25,000,
$25,000 - $49,000, $50,000 - $74,999 and greater than $75,000. Smoking status and
alcohol consumption were dichotomized as none current smoker and current smoker,
none regular drinker and regular drinker, respectively. Body Mass Index (BMI) was
determined as four categories: Less than 18.5, 18.5 to 24.99, 25-29.99 and greater than
30. Lipid profiles including total cholesterol (TLC), Triglycerides, Low density lipoprotein
(LDL); High density lipoprotein (LDL) were categorized as the levels based on the
American Heart Association (AHA) recommends. For the TCL levels: less than 200
mg/dL, 200-239 mg/dL, greater that 240 mg/dL; Level of Triglycerides levels: less than
150 mg/dL, 150-199 mg/dL, 200-500 mg/dL and greater than 500mg/dL. Level of LDL:
less than 129 mg/dL, 130-159 mg/dL, 160-190 mg/dL and greater than 190 mg/dL.
Level of HDL: less than 40 mg/dL, 40-60 mg/dL and greater than 60 mg/dL,
respectively.

III.III Definition of Variables of the Comorbidities
The comorbidities of AMD for cardiovascular diseases were defined based on the
questionnaire and medical laboratory examination. The self reported questions were
used to define some of comorbidities, and the subjects were asked similar questions,
including coronary heart disease (“Has a doctor or other health professional ever told
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you that you had a coronary heart disease?”), congestive heart failure (“Has a doctor or
other health professional ever told you that you had congestive heart failure?”), stroke
(“Has a doctor or other health professional ever told you that you had a stroke?”) and
angina pectoris (“Has a doctor or other health professional ever told you that you had an
angina pectoris?”), and heart attack ("Has a doctor or other health professional ever told
you that you had Heart Attack?"). Chronic Kidney Disease (CKD) is defined by self
report and estimation of glomerular filtration rate (GFR). All individuals with GFR <60
mL/min/1.73 m2 are classified as CKD. GFR estimation was done according to
Epidemiology Collaboration equation. Serum creatinine values were collected from the
NHANES dataset. Persistent presence of more than 30 mg albumin per gram creatinine
in the urine is diagnostic of chronic kidney disease. Microalbuminuria is a level of 30–
299 mg/L (Bowling, Sharma, Fox, O'Hare, & Muntner, 2013).

III.IV Retinal Imaging Evaluation
Procedures for ophthalmological retinal imaging evaluation have been described
previously (Klein, et al., 1999). The retinal imaging evaluation was adapted from the
Wisconsin Age-Related Maculopathy Grading Scheme (Klein et al., 1991). The
presence of any drusen, soft drusen, retinal pigment epithelial (RPE) depigmentation
and increased retinal pigment were assessed. GA was determined by absence of the
RPE in which choroidal vessels are visible. The signs of CNV contain subretinal
hemorrhage and fibrous scar, and retinal pigment epithelium detachment. Early AMD
was determined by the presence of either soft drusen consistent with Grade 3 drusen or
any drusen type with areas of depigmentation or hypopigmentation of the retinal
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pigment epithelium without any visibility of choroidal vessels or with increased retinal
pigment in the macular area. Late AMD was determined by the presence of signs of
CNV or GA. RPE depigmentation was graded as present or absent. Increased retinal
pigment which is the presence of granules or clumps of gray or black pigment in or
beneath the retina was graded as present or absent. Retinal photograph was taken
under a dilated eye. Retinal image is the field centered horizontally and vertically.

III.V Statistical Analysis
All analyses were conducted by using SAS 9.3 (SAS Institute, Cary, NC).
Frequency distributions, percentages and means, and standard deviation were used to
describe the difference of sociodemographic characteristics of the NHANES study
population relating to AMD. The significance of the differences among categorical
variables were determined by Chi square statistics, and Wilcoxon Rank Sum were used
to test the difference among continuous variables based on the sample distribution and
equality of variance. Univariate and multiple logistic regression models were used to
assess the association between AMD and potential confounders including age, gender,
race/ethnicity, alcohol consumption, education level, smoking status, and annual family
income. Full sample 2 year interview and MEC exam weight were used to weight all
survey samples. All analysis used weighted and stratified sample.
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CHAPETER IV
RESULTS
IV.I Prevalence of AMD Stratified by Age in NHANES Population 2005 - 2008
The total number of participants who were aged 40 years or older were 4596 with
a completion of examination of retinal image. Among them, the number of people who
had AMD were 441. The overall weighted prevalence of AMD was 7%. Compared to
the individuals whose age were 40-49 years old, the weighted prevalence of AMD were
10% for those aged 70 years or older, 5% for those aged 60- 69 years, and 2% for
those 50-59 years, respectively (Table1).

Table 1. Weighted prevalence of AMD stratified by age: Adults 40 years or older, 2005 -2008 NHANES
Participation's age (Years ) (OR, 95 %CI )
Outcome

AMD

40 - 49

50 - 59

60 - 69

70 or older

1.00

1.90

4.53

9.85

(Reference)

(1.89-1.91)

( 4.512 - 4.534)

( 9.83 - 9.88 )

IV.II Descriptive Analysis of Study Population with or without of AMD
The characteristics of 2005-2008 NHANES population with or without AMD was
summarized in Table 2. Briefly, average of the age among individuals with AMD was 68
years old, and 87% of study population was whites, which were significantly higher than
those among the individuals without AMD ( Age: 56, Whites: 76%, P value <0.05). The
gender did not differ between two groups. The proportion of annual family incomes
among the individuals with AMD was significantly difference from those among the
participants without AMD (P value <0.05). The proportion of annual family incomes
greater than $75K in individuals with AMD was 10%, which was significantly lower than
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those among the individuals without AMD (22%). Level of education did not differ
between individuals without or with AMD. The proportion of current smokers with AMD
(15%) was lower comparing to those without AMD (19%, P value <0.05) in this
population. The proportion of AMD among the regular alcohol drinker (47%) was lower
compared to those without AMD (60%, P-value<0.05). The level of HDL was
significantly differ between AMD and non AMD participants (P<0.05); whereas, the
levels of TCL, triglycerides and LDL were not statistically different (Table 2).
Table 2. Characteristics of participants with or without AMD: Adults aged 40 years or
older, AMD defined by retinal photography, NHANES 2005-2008

Characteristics

No AMD a

AMD a

(N= 4596)

(N =441)

55.6 (55.2-55.9)

68.0 (66.4-69.6)

P value c

Demographic
Age (year)

b

Gender

<0.0001
0.8960

Male

47.4 (45.7-49.2)

47.0 (41.3-52.8)

Female

52.6 (50.8-54.3)

53.0 (47.2-58.7)

Race/ Ethnicity

<0.0001

Non-Hispanic Whites

76.4 (75.3-77.6)

86.6 (83.6-90.0 )

Non-Hispanic Blacks

8.1 (7.2-9.0)

3.76 (2.4-5.1 )

Mexican American

8.1 (7.2-9.0)

5.5 (3.2-7.8)

The others

5.5 (5.1-5.9)

4.2 (2.9-5.5 )

Socioeconomic
Education

0.0736

High school graduate

44.0 (42.2-45.7)

49.6 (43.9-55.3 )

College or Associate

28.3 (26.8-29.9)

28.8 (23.5-34.1 )

College graduate or above

27.7 (26.1-29.3)

21.6 (16.6-26.6 )

Family annual income

<0.0001
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<$25,000

26.0 (24.6-27.5)

36.4 (30.8-42.0)

$25,000-$4999

35.2 (34.4-38.0)

41.1(35.0-47.2)

$50,000-$74999

16.5 (15.0-18.0)

12.2 ( 7.3-17.0)

>$75,000

22.2 (20.6-23.9)

10.4 (6.3-14.5)

Smoking status

0.0203

None current smoker

81.3 (80.0-90.0)

85.0 (80.7-89.4)

Current smoker

18.7 (17.3-20.0)

15.0 (10.6-19.3)

Alcohol consumption

0.0079

None regular drinker

39.6 (36.6-42.7)

53.1 (43.5-63.7)

Regular drinker

60.4 (57.3-63.4)

46.9 (37.3-56.5 )

Medical examinational
Body Mass Index (BMI)

0.0654

<18.5

2.0 (1.6-2.5)

1.1 (0.2-2.0 )

18.5 -24.99

26.0 (24.5-27.6)

29.9 (24.5-35.3)

25-29.99

35.1 (33.4-36.7)

38.3 (32.7-43.8 )

>30

36.9 (35.2-38.5)

30.7 (25.4-36.0)

Total Cholesterol (mg/dL )

0.7235

<200

50.3 (48.5-52.0)

50.7 (45.0-56.5)

200-239

31.8 (30.2-33.5)

33.2 (27.6-38.8)

>240

17.9 (16.5-19.2)

16.1 (11.9 -20.3)

Triglycerides (mg/dL)

0.2465

<150

83.8 (82.5-85.1)

85.8 (82.1-90.0)

150-199

7.9 (6.9-8.8)

6.2 (3.8-8.7)

200-500

3.7 (3.1-4.4)

4.9 (2.6-7.3)

> 500

4.6 (3.9-5.3)

3.0 (1.1-4.9)

LDL (mg/dL)

0.8518

<129

82.6 (81.2 -83.9)

80.7 (75.7-85.7)

130-159

11.8 (10.7-12.9)

13.5 (9.0-17.9)

160-190

4.1 (3.4-4.8)

4.4 (1.9-7.0)

>190

1.6 (1.1-2.0)

1.4 (0.2-2.6)

HDL (mg/dL)

0.0288

<40

20.1 (18.7-21.5)

17.2 (12.9-21.5)

40-60

49.8 (48.1-51.6)

45.2 (39.5-50.9)

> 60

30.1 (28.5-31.8)

37.5 (31.9-43.2)
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Values for categorical variables presented weighted proportion and 95% CI , and P-values were
generated by Chi square test. Values for continues variables were weighted mean and 95% CI and Pa
b
c
values were generated by F-test . = % (95% CI); = mean (95% CI). = P value <0.05. LDL: Low
density lipoprotein; HDL: High density lipoprotein; CI: Confidence interval.

We also compared these sociodemographic characteristics among the
individuals with early or late AMD to those without AMD. These characteristics of early
AMD results were similar to the participants without AMD, however, the mean of age
(78 years) among the individuals with late AMD were significantly older than those with
early AMD (67 years), and higher proportion of whites in late AMD participants (94%, Pvalue <0.05) were observed compared with early AMD (86%). Females with late AMD
were more likely to have AMD (70% versus 52% early AMD) (Table 3).

Table 3. Characteristics of participants with early/late AMD: Adults aged 40 years or older,
AMD defined by retinal photography, NHANES 2005-2008

Characteristics

Early AMD a

Late AMD a

(N=441)

(N =51)

P value c

Demographic
Age (year)

b

66.6(64.9-68.3)

78.0 (76.2-80.0)

Gender

<0.0001
0.0724

Male

49.4 (43.9-55.6)

30.1 (17.4-42.8)

Female

52.2 (46.2-58.2)

69.7 (57.2-82.6)

Race/ Ethnicity

<0.0001

Non-Hispanic Whites

86.0 (82.8-89.1)

94.4 (89.4-99.2)

Non-Hispanic Blacks

5.6 (3.1-8.0)

2.2 (0-5.5)

Mexican American

4.7 (3.2-6.2)

0.6 (0-1.8)

The others

4.0 (2.5-5.5)

0.5 (0-6.2)

Socioeconomic
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Education

0.1028

High school graduate

49.2 (43.0-55.5)

52.1 (37.8-66.5)

College or Associate

27.6 (22.2-33.1)

37.8 (21.0-48.6)

College graduate or above

22.4 (17.1-27.8)

13.1 (3.2-23.0)

Family annual income

<0.0001

<$25,000

33.9 (29.5-41.1)

53.0 (37.5-68.5)

$25,000-$4999

41.1 (34.5-47.7)

40.8 (25.2-56.3)

$50,000-$74999

13.9 (8.5-19.4)

0

>$75,000

11.0 (6.4-15.6)

6.2 (0-13.4)

Smoking status

0.1596

None current smoker

85.0(80.3-90.0)

89.2 (80.3-98.0)

Current smoker

15.0 (10.2-19.7)

10.9 (2.0-19.7)

Alcohol consumption

0.0024

None regular drinker

49.0 (38.3-59.8)

73.2 (55.6-90.9)

Regular drinker

51.0 (40.2-61.7)

26.8 (9.1-44.5)

Medical examinational
Body Mass Index (BMI)

0.0338

<18.5

0.9 (0-1.8)

2.4 (0-5.7)

18.5 -24.99

28.9 (23.0-34.7)

37.3 (23.2-51.5)

25-29.99

37.4 (31.4-43.3)

44.6 (30.3-58.8)

>30

32.8 (27.0-38.6)

15.7 (6.2-25.1)

Total Cholesterol (mg/dL )

0.5664

<200

50.6 (44.4-56.9)

51.3 (37.0-65.6)

200-239

34.3 (8.2-40.4)

25.3 (13.1-37.4)

>240

15.1(10.6-19.5)

23.4(11.3-35.5)

Triglycerides (mg/dL)
<150

0.5731
86.2 (82.2-90.1)
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83.5 (72.4-94.6)

150-199

6.0 (3.4-8.5)

8.3 (0.1-16.5)

200-500

4..8 (2.3-7.3)

5.9 (0-13.2)

> 500

3.1 (1.0-5.1)

2.2 (0-6.6)

LDL (mg/dL)

0.9134

<129

80.6 (75.1-86.0)

81.8 (70.6-92.9)

130-159

13.9 (9.0-18.8)

10.1 (0.8-19.3)

160-190

4.3 (1.6-7.1)

5.2 (0-11.0)

>190

1.2 (0-2.4)

2.3 (0-7.5)

HDL (mg/dL)

0.0411

<40

18.3 (13.5-23.0)

9.7 (1.3-18.1)

40-60

45.1 (38.9-51.3)

46.2 (32.0-60.5)

> 60

36.6 (30.5-42.7)

44.1 (30.0-58.4)

See Table 1's footnote. P-values presented the comparisons of either early or late AMD to none-AMD
(iiTable 2).

IV.III Prevalence of Vascular and Renal Comorbidities and AMD in the 2005-2008
NHANE
The proportions of these comorbidities were estimated in the individuals with or
without AMD by using the NHANES data combining 2 surveys. Among the individuals
with AMD, 6% had AP, 10% had CHD, 7% had CHF, 10% had MI, 13% had stroke, and
29% had CKD. The weighted prevalence were significantly higher than those among
individuals without AMD (AP: 3%; CHD: 5%; CHF: 3%; MI: 5%; Stroke: 4%; CKD: 12%,
P-value <0.05) (Table4).
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Table 4. Weighted prevalence of vascular and renal comorbidities with or without AMD:
Adults aged 40 years or older, AMD defined by retinal photography, 2005-2008 NHANES
No AMD

AMD

Medical conditions

Weighted %(95%CI)

Weighted %(95%CI)

P value

Angina Pectoris (AP)

3.2 (2.7-3.7)

6.1 (3.7-8.5)

0.0033

Coronary heart disease (CHD)

4.5 (3.8-5.1)

10.3 (7.0-13.6)

<0.0001

Congestive heart failure (CHF)

3.0 (2.6-3.5)

7.3 (4.5-10.2 )

<0.0001

Myocardial Infarction (MI)

4.5( 3.9-5.2)

10.1 ( 7.0-13.2)

<0.0001

Stroke

3.5 (3.0-4.1 )

12.5 ( 9.0-16.1)

<0.0001

Chronic Kidney Disease (CKD)

10.8 (9.8-11.8 )

28.8(23.8-33.8)

<0.0001

Values present weighted proportion (%) and 95% Confidence interval (CI). Rao-Scott Chi-Square
statistics were used for the comparison between no AMD and AMD.

When we examined the weighted prevalence of these comorbidities among the
individuals with early or late AMD, results were similar; however, the proportions of
stroke (26%) and CKD (49%) in the participants with late AMD were significantly higher
than those without AMD (P value<0.05) (Table 5 ).
Table 5.Weighted prevalence of the cormorbidites with early or late AMD or without AMD:
Adults aged 40 years or older, AMD defined by retinal photography, 2005-2008 NHANES
No AMD

Early AMD

Late AMD

Medical

Weighted %
(95%CI)

Weighted
%(95%CI)

P value

conditions

Weighted
%(95%CI)

AP

3.2 (2.7-3.7)

6.6 (3.9-9.3)

2.1 (0-5.3)

0.009

CHD

4.5 (3.8-5.1)

10.2 (6.6-13.8)

10.6 (2.3-19.1)

<0.0001

CHF

3.3 (2.6-3.5)

6.5(3.5-9.4)

13.4 (3.5-23.3)

<0.0001

MI

4.5( 3.9-5.2)

10.2 (6.8-13.6)

9.3 (2.0-16.6)

<0.0001

Stroke

3.5 (3.0-4.1 )

10.7(7.2-14.3)

26.4(13.2-39.5)

<0.0001

CKD

10.8 (9.8-11.8 )

26.0 (20.7-31.2)

49.4 (35.1-63.8)

<0.0001

Values present weighted proportion (%) and 95% Confidence interval (CI). Rao-Scott Chi-Square
statistics were used for the comparison between no AMD and early/late AMD.
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IV.IV Association Between Each Single Comorbidity and AMD in the 2005-2008 NHANE
To address the association of each single vascular and renal comorbidity with
AMD, we, first, conducted univariate logistic regression analysis. ORs were estimated.
The crude ORs for all AMD among the participants with these conditions (AP, CHD, MI,
CHF, HD and stroke) were 2.0 (95% CI:1.2-3.1), 2.5 (95% CI: 1.7-3.6), 2.4 (95% CI:
1.6-3.5), 2.5 (95% CI: 1.6-4.0), 2.6 (95%CI: 2.0-3.4) and 3.9 (2.7-4.4), respectively. In
addition, the crude OR for AMD was 3.4 (95%CI: 2.6-4.4) among the individuals with
CKD. After controlling for gender, age, race/ethnicity, current smoke status, alcohol
consumption, and annual family incomes, and level of serum HDL, the adjusted ORs for
AMD were similar to the crude ORs among the individuals with CHD (2.3, 95% CI: 1.43.7), MI (2.2, 95% CI: 1.3-3.5), CHF (2.0, 95% CI: 1.1-3.8), HD (2.0, 95% CI: 1.4- 2.9),
and stroke (3.0, 95%CI: 1.8-4.9) and CKD ( 2.4, 95%CI: 1.7-3.4), respectively; however,
the adjusted OR for the AMD among the individuals with AP was no longer significant
(1.5, 95% CI: 0.8-2.7). We also examined the crude and adjusted ORs for early AMD
using the same logistic regression models, similar results were observed (Table 6).
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Table 6. Association between a single comorbidity and AMD, respectively : Adults age 40
years or older, AMD defined by retinal photography, 2005-2008 NHANES
AMD
Medical conditions

Early AMD

Crude OR

Adjusted OR

Crude OR

Adjusted OR

( 95%CI )

( 95%CI )

( 95%CI )

( 95%CI )

AP

1.96 (1.24-3.10)

1.50 (0.83-2,71)

2.05 (1.29-3.27)

1.59 (0.88-2.87)

CHD

2.46 (1.67-3.64)

2.27 (1.35-3.67)

2.44 (1.63-3.66)

2.17 (1.30-3.62)

MI

2.38 (1.64-3.45)

2.20 (1.34-3.51)

2.34 (1.59-3.44)

2.12 (1.29-3.49)

CHF

2.51 (1.60-3.95)

1.98 (1.05-3.75)

2.44 (1.52-3.92)

2.09 (1.10-3.97)

HD

2.59 (1.95-3.43)

2.01 (1.38-2.93)

2.57 (1.91-3.45)

2.04 (1.39-3.00)

Stroke

3.91 (2.72-4.36)

2.99(1.82-4.92)

2.37 (2.55-5.44)

2.12 (0.57-7.80)

CKD

3.35 (2.57-4.36)

2.44 (1.73-3.43)

2.99 (2.26-3.96)

2.32 (1.63-3.31)

Adjusting factors: Gender, age race/ethnicity, smoking, alcohol consumption, and annual family incomes,
and level of HDL Abbreviations: HD: either AP or CHD or CHF or MI. OR, odds ratio

IV.V Association of Combination of Comorbidities and AMD
To investigate whether there is a strong association of these comorbidities with
AMD, we conducted the logistic regression analysis with. Without any condition was
defines as a reference group. We found that crude ORs for AMD were 2.8 (95% CI: 2.93.9) among the individuals with any one condition, 3.9 (95% CI: 2.7-5.7) among the
participants with any two conditions or more. The association was statistically significant
(P-value <0.05). After controlling for age, gender, race/ethnicity, smoking status, alcohol
consumption and annual family incomes, and the level of HDL, the association
remained a significant level (P-value <0.05). We also examined whether the c
association was presented in early AMD (P<0.05). The results were similar (Table 7).
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Table 7. Association of combination of comorbidity with AMD: Adults aged 40 years or older,
AMD defined by retinal photography, 2005-2008 NHANES
AMD
Medical conditions

Early AMD

Crude OR
(95%CI)

Adjusted OR
(95%CI)

Crude

Adjusted OR

OR (95%CI)

(95%CI)

None (Reference)

1.00

1.00

1.00

1.00

Any one

2.78 (2.00-3.87)

2.60 (1.71-3.92)

2.67 (1.89-3.77)

2.56 (1.68-3.92)

Any two or more

3.93 (2.69-5.73)

2.33 (2.73-3.99)

3.60 (2.42-5.36)

2.31 (1.33-4.01)

Adjusting factors: Gender, age race/ethnicity, smoking, alcohol consumption, and annual family
incomes and level of HDL. Abbreviations: one condition, either HD or CKD or stroke; two
conditions, any combination of two among HD, CKD and stroke; OR, odds ratio.

IV.VI Association of Specific Combination of Comorbidities with AMD in the 2005-2008
NHANES
To estimate whether there is an association among a specific combination of
these comorbidities, we analyzed the ORs for AMD among three specific combinations
of comorbidities (HD/Stroke, HD/CKD and Stroke/CKD) using the same logistic
regression model designed above with same controlling factor. We found that the crude
ORs for AMD were 4.0 (95%CI: 3.3-7.0), 3.9 (2.6-5.8) and 7.4 (4.5-12.2) among the
individuals with HD/Stroke, HD/CKD and Stroke/CKD, respectively. With controlling for
the adjusted factors, the associations remained same. In addition, we estimated these
associations for early AMD, the results were similar (Table 8)
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Table 8. Association of specific combination of co-morbidity with AMD: Adults aged 40 years or
older, AMD defined by retinal photography, 2005 - 2008 NHANES
AMD
Medical conditions

Early AMD

Crude

Adjusted

Crude

Adjusted

OR ( 95%CI )

OR ( 95%CI )

OR ( 95%CI )

OR ( 95%CI )

HD/Stroke

404 (2.34-6.96)

2.25 (1.00-5.07)

4.16 (2.39-5.26)

2.37 (1.06-5.33)

HD/ CKD

3.88 (2.58-5.80)

2.43 (1.36-4.34)

3.40 (2.19-5.26)

2.39 (1.31-4.33)

Stroke/ CKD

7.43 (4.51-12.27)

5.50 (2.74-11.02)

6.92 (4.12-11.61)

5.87(2.94-11.74)

Adjusting factors: Gender, age race/ethnicity, smoking, alcohol consumption, and annual family incomes
and level of HDL
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CHAPTER V
DISCUSSION AND CONCLUSIONS
The association of vascular or renal comorbidities with AMD has been reported
inconsistently with some studies showing a significant association, and others not
showing the association. To our knowledge, this study is first to investigate a
relationship of combination of these comorbidities with AMD by utilizing the large
nationally representative sample of US. We found that the prevalence of six vascular
and renal conditions (AP, CHD, CHF, MI, Stroke and CKD) among individuals with AMD
was significantly higher than those without AMD. Each of six comorbidities was
significantly associated with AMD by the analysis of univariate logistic regression,
respectively; whereas, the association was no longer existing in individuals with AP,
other conditions remained the association, after controlling for age, gender,
race/ethnicity, family annual income, smoking status, alcohol consumption and the level
of HDL. Comparing to individuals without three conditions (HD, Stroke and CKD), the
crude ORs of AMD increased 2-fold with the presence of any one and 4-fold with any
two conditions and more, respectively. The adjusted ORs were attenuated, but
remained significantly difference. Furthermore, the individuals with both stroke and CKD
were strongly associated with AMD. Correspondently, we found that the prevalence of
both stroke and CKD among individuals with AMD were approximately 3 times higher
than those among individuals without AMD. Similar results were observed in early
AMD. The findings may provide insight for appropriate preventive measurement for
health care management.
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Our results indicate that there is an association of vascular and renal
comorbidities with AMD. Several possible reasons that would explain it. AMD shares
common risk factors with these comorbidities, for example, smoking (Erke et al., 2014;
Snow & Seddon, 1999). The pathological regions for these three comorbidities are all
involved with the abnormalities of blood vessels. The abnormalities are commonly
correlated to atherosclerosis. AMD shares pathological similarities with atherosclerosis
(Machalinska, Kawa, Marlicz, & Machalinski, 2012). According to the association seen
in this study, a potential hypothesis is that atherosclerosis occurred at the choroidial
circulation may contribute to the development of AMD. Dyslipidemia is well-known risk
factor of vascular diseases. Reducing the level of HDL could lead to preventive
outcomes (Schaefer, 2012). The high level of HDL seen in the AMD participants in this
study reveals that the dyslipidemia may be a common risk factor of AMD and vascular
and renal diseases. It shed the light that reducing the level of HDL would lead to the
potential prevention of development of AMD. The most recent study revealed an
association of cholesteryl ester transfer protein (CETP) gene with neovascular AMD (Liu
et al., 2014), Out results might indicate a potential to investigate the gene-related
relationship not only in neovascuar AMD, but in all type of AMD.
The most interesting finding of this study is a strong relationship of combination
of stroke and CKD with AMD. Microvascular alteration in the retinal circulation and the
retinal pigment epithelium play important roles in the pathology of AMD. Kidney damage
generally is considered from burden of microvascular and systematic epithelium.
Furthermore, genetic predisposition of kidney disease and AMD share similar
involvement of alternative complement pathway (Ansari et al., 2013; Ma et al., 2014;
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Zhan et al., 2013). Both common shared pathological pathways and genetic
predisposition similarities, therefore, may explain the strong association of the
combination of the comorbidities with AMD, particularly in the combination of stroke and
CKD. .
There are important implications of our results. The estimates of prevalence in
this study provide the probabilities of presence of these comorbidities, the presence of
higher probabilities among individuals with AMD compared with those without AMD
should trigger a further longitudinal study for the potential coexistence of these
comorbidities. If there is temporal relationship between comorbidities and AMD, these
vascular and renal comorbidities will need to be recognized as a potential risk factor of
AMD. These comorbidities should be managed and measured in the AMD care
management.
Management of AMD should take into account these vascular and renal diseases
because coexisting these comorbidities and AMD will lead the worse health outcome.
These comorbidities could be potential risk factor indicators for eye care management in
order to early detect AMD. For example, increased frequency of regular eye
examination among people who have these comorbidities would be ideal. Furthermore,
the preventive strategies and managements for vascular and renal disease could be
applied to AMD-risk population. For instance, change in the life style behavior, such as
physical activity.
Strengths and limitation of this study deserve to be discussed. This study was
using nationally representatively sample of US with a continuous 2 years surveys,
therefore, the results more likely lead to generalizability of US population. Also,
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standardized retinal image examination was conducted to our study, and individuals
with a completion of the retinal image examination were include in the study population
to determine the presence of drusen and pigment alteration, this minimized the
misclassification of diagnosis of AMD, while the cross-sectional study design can not
address a potential temporal relationship between these comorbidities and AMD.
Further research for longitudinal studies would be desirable to investigate the plausible
relationship. In order to minimize the misclassification from self-reported diagnosis for
the comorbidities related to heart diseases, the variable of heart disease was defined by
mutual exclusive of each heart condition. Thus, it is unlikely that misclassification of
diagnosis would explain the strong association observed in this study.

In conclusion, these findings from a nationally representative US population
highlight the remarkable association between vascular and renal comorbidities of AMD.
Give the worse outcome of AMD associated with these comorbidities, these
comorbidities should be take account into the eye care management for not only AMD
patient, but also AMD-risk population. The preventive strategies for vascular and renal
conditions should be preferred to be applied to AMD care management.
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ABBREVIATIONS
AP: Angina Pectoris
AMD: Age-related macular degeneration
CHD: Coronary heart disease
CHF: Congestive heart failure
CI: Confidence Interval
HD: Heart disease
MI: Myocardial Infarction
CKD: Chronic kidney disease

42

REFERENCES
Akpek, E. K., & Smith, R. A. (2013). Current treatment strategies for age-related ocular conditions. Am J Manag
Care, 19(5 Suppl), S76-84.
Ansari, M., McKeigue, P. M., Skerka, C., Hayward, C., Rudan, I., Vitart, V., et al. (2013). Genetic influences on
plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular
degeneration. Hum Mol Genet, 22(23), 4857-4869.
Bourne, R., Price, H., Taylor, H., Leasher, J., Keeffe, J., Glanville, J., et al. (2013). New systematic review
methodology for visual impairment and blindness for the 2010 Global Burden of Disease study.
Ophthalmic Epidemiol, 20(1), 33-39.
Bowling, C. B., Sharma, P., Fox, C. S., O'Hare, A. M., & Muntner, P. (2013). Prevalence of reduced estimated
glomerular filtration rate among the oldest old from 1988-1994 through 2005-2010. JAMA, 310(12), 12841286.
Chaine, G., Hullo, A., Sahel, J., Soubrane, G., Espinasse-Berrod, M. A., Schutz, D., et al. (1998). Case-control study
of the risk factors for age related macular degeneration. France-DMLA Study Group. Br J Ophthalmol,
82(9), 996-1002.
Chakravarthy, U., Wong, T. Y., Fletcher, A., Piault, E., Evans, C., Zlateva, G., et al. (2010). Clinical risk factors for
age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol, 10, 31.
Cherepanoff, S., McMenamin, P., Gillies, M. C., Kettle, E., & Sarks, S. H. (2010). Bruch's membrane and choroidal
macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol, 94(7), 918-925.
Chew, E. Y., Clemons, T. E., Agron, E., Sperduto, R. D., Sangiovanni, J. P., Kurinij, N., et al. (2013). Long-term
effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report
no. 35. Ophthalmology, 120(8), 1604-1611 e1604.
Choi, J., Moon, J. W., & Shin, H. J. (2011). Chronic kidney disease, early age-related macular degeneration, and
peripheral retinal drusen. Ophthalmic Epidemiol, 18(6), 259-263.
Chou, C. F., Cotch, M. F., Vitale, S., Zhang, X., Klein, R., Friedman, D. S., et al. (2013). Age-related eye diseases
and visual impairment among U.S. adults. Am J Prev Med, 45(1), 29-35.
Donnan, G. A., Fisher, M., Macleod, M., & Davis, S. M. (2008). Stroke. Lancet, 371(9624), 1612-1623.
Duan, Y., Mo, J., Klein, R., Scott, I. U., Lin, H. M., Caulfield, J., et al. (2007). Age-related macular degeneration is
associated with incident myocardial infarction among elderly Americans. Ophthalmology, 114(4), 732-737.
Erke, M. G., Bertelsen, G., Peto, T., Sjolie, A. K., Lindekleiv, H., & Njolstad, I. (2014). Cardiovascular risk factors
associated with age-related macular degeneration: the Tromso Study. Acta Ophthalmol.
Fagerness, J. A., Maller, J. B., Neale, B. M., Reynolds, R. C., Daly, M. J., & Seddon, J. M. (2009). Variation near
complement factor I is associated with risk of advanced AMD. Eur J Hum Genet, 17(1), 100-104.
Fernandez, A. B., Wong, T. Y., Klein, R., Collins, D., Burke, G., Cotch, M. F., et al. (2012). Age-related macular
degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.
Ophthalmology, 119(4), 765-770.
Foran, S., Wang, J. J., & Mitchell, P. (2003). Causes of visual impairment in two older population cross-sections:
the Blue Mountains Eye Study. Ophthalmic Epidemiol, 10(4), 215-225.
Gao, B., Zhu, L., Pan, Y., Yang, S., Zhang, L., & Wang, H. (2011). Ocular fundus pathology and chronic kidney
disease in a Chinese population. BMC Nephrol, 12, 62.
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. (2013). Heart disease
and stroke statistics--2013 update: a report from the American Heart Association. Circulation, 127(1), e6e245.
Golan, S., Shalev, V., Goldstein, M., Treister, G., Chodick, G., & Loewenstein, A. (2011). The rate of myocardial
infarction events among patients with age-related macular degeneration: a population-based study. Graefes
Arch Clin Exp Ophthalmol, 249(2), 179-182.
Heurich, M., Martinez-Barricarte, R., Francis, N. J., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P., et al.
(2011). Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic
complement activity and disease risk. Proc Natl Acad Sci U S A, 108(21), 8761-8766.
Hollyfield, J. G., Bonilha, V. L., Rayborn, M. E., Yang, X., Shadrach, K. G., Lu, L., et al. (2008). Oxidative
damage-induced inflammation initiates age-related macular degeneration. Nat Med, 14(2), 194-198.
Hu, C. C., Ho, J. D., & Lin, H. C. (2010). Neovascular age-related macular degeneration and the risk of stroke: a 5year population-based follow-up study. Stroke, 41(4), 613-617.
Ikram, M. K., Mitchell, P., Klein, R., Sharrett, A. R., Couper, D. J., & Wong, T. Y. (2012). Age-related macular
degeneration and long-term risk of stroke subtypes. Stroke, 43(6), 1681-1683.

43

Klein, R., Chou, C. F., Klein, B. E., Zhang, X., Meuer, S. M., & Saaddine, J. B. (2011). Prevalence of age-related
macular degeneration in the US population. Arch Ophthalmol, 129(1), 75-80.
Klein, R., Cruickshanks, K. J., Myers, C. E., Sivakumaran, T. A., Iyengar, S. K., Meuer, S. M., et al. (2013). The
relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: the
Beaver Dam studies. Ophthalmology, 120(5), 1012-1019.
Klein, R., Cruickshanks, K. J., Nash, S. D., Krantz, E. M., Nieto, F. J., Huang, G. H., et al. (2010). The prevalence
of age-related macular degeneration and associated risk factors. Arch Ophthalmol, 128(6), 750-758.
Klein, R., Davis, M. D., Magli, Y. L., Segal, P., Klein, B. E., & Hubbard, L. (1991). The Wisconsin age-related
maculopathy grading system. Ophthalmology, 98(7), 1128-1134.
Klein, R., Klein, B. E., Jensen, S. C., Mares-Perlman, J. A., Cruickshanks, K. J., & Palta, M. (1999). Age-related
maculopathy in a multiracial United States population: the National Health and Nutrition Examination
Survey III. Ophthalmology, 106(6), 1056-1065.
Klein, R., Klein, B. E., Knudtson, M. D., Meuer, S. M., Swift, M., & Gangnon, R. E. (2007). Fifteen-year
cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology,
114(2), 253-262.
Klein, R., Knudtson, M. D., Lee, K. E., & Klein, B. E. (2009). Serum cystatin C level, kidney disease markers, and
incidence of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol, 127(2), 193199.
Leibowitz, H. M., Krueger, D. E., Maunder, L. R., Milton, R. C., Kini, M. M., Kahn, H. A., et al. (1980). The
Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma,
diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 19731975. Surv Ophthalmol, 24(Suppl), 335-610.
Lengyel, I., Tufail, A., Hosaini, H. A., Luthert, P., Bird, A. C., & Jeffery, G. (2004). Association of drusen
deposition with choroidal intercapillary pillars in the aging human eye. Invest Ophthalmol Vis Sci, 45(9),
2886-2892.
Liew, G., Mitchell, P., Wong, T. Y., Iyengar, S. K., & Wang, J. J. (2008). CKD increases the risk of age-related
macular degeneration. J Am Soc Nephrol, 19(4), 806-811.
Liu, K., Chen, L. J., Lai, T. Y., Tam, P. O., Ho, M., Chiang, S. W., et al. (2014). Genes in the High-Density
Lipoprotein Metabolic Pathway in Age-related Macular Degeneration and Polypoidal Choroidal
Vasculopathy. Ophthalmology, 121(4), 911-916.
Liutkeviciene, R., Lesauskaite, V., Zaliuniene, D., Zaliaduonyte-Peksiene, D., Cimbalas, A., Jasinskas, V., et al.
(2012). Early age-related macular degeneration in patients with myocardial infarction. Curr Eye Res, 37(2),
94-100.
Ma, R., Cui, Z., Hu, S. Y., Jia, X. Y., Yang, R., Zheng, X., et al. (2014). The alternative pathway of complement
activation may be involved in the renal damage of human anti-glomerular basement membrane disease.
PLoS One, 9(3), e91250.
Machalinska, A., Kawa, M. P., Marlicz, W., & Machalinski, B. (2012). Complement system activation and
endothelial dysfunction in patients with age-related macular degeneration (AMD): possible relationship
between AMD and atherosclerosis. Acta Ophthalmol, 90(8), 695-703.
Nguyen-Khoa, B. A., Goehring, E. L., Jr., Werther, W., Gower, E. W., Do, D. V., & Jones, J. K. (2008).
Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol,
126(9), 1280-1286.
Nitsch, D., Evans, J., Roderick, P. J., Smeeth, L., & Fletcher, A. E. (2009). Associations between chronic kidney
disease and age-related macular degeneration. Ophthalmic Epidemiol, 16(3), 181-186.
Owen, C. G., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A. E., & Rudnicka, A. R. (2012). The estimated
prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol, 96(5),
752-756.
Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., et al. (2008). Heart disease and stroke
statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Circulation, 117(4), e25-146.
Schaefer, J. R. (2012). [HDL level or HDL function as the primary target in preventive cardiology]. Herz, 37(1), 5155.
Snow, K. K., & Seddon, J. M. (1999). Do age-related macular degeneration and cardiovascular disease share
common antecedents? Ophthalmic Epidemiol, 6(2), 125-143.
Sun, C., Klein, R., & Wong, T. Y. (2009). Age-related macular degeneration and risk of coronary heart disease and
stroke: the Cardiovascular Health Study. Ophthalmology, 116(10), 1913-1919.

44

Tan, J. S., Wang, J. J., Liew, G., Rochtchina, E., & Mitchell, P. (2008). Age-related macular degeneration and
mortality from cardiovascular disease or stroke. Br J Ophthalmol, 92(4), 509-512.
Tomany, S. C., Wang, J. J., Van Leeuwen, R., Klein, R., Mitchell, P., Vingerling, J. R., et al. (2004). Risk factors for
incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology, 111(7),
1280-1287.
van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L., & Ye, W. (2014). Mechanisms of age-related macular
degeneration and therapeutic opportunities. J Pathol, 232(2), 151-164.
Whitcup, S. M., Sodhi, A., Atkinson, J. P., Holers, V. M., Sinha, D., Rohrer, B., et al. (2013). The role of the
immune response in age-related macular degeneration. Int J Inflam, 2013, 348092.
Wieberdink, R. G., Ho, L., Ikram, M. K., Koudstaal, P. J., Hofman, A., de Jong, P. T., et al. (2011). Age-related
macular degeneration and the risk of stroke: the Rotterdam study. Stroke, 42(8), 2138-2142.
Wlodarek, D., & Glabska, D. (2011). [Influence of the lutein-rich products consumption on its supply in diet of
individuals with age-related macular degeneration (AMD)]. Klin Oczna, 113(1-3), 42-46.
Wolff, J. L., Starfield, B., & Anderson, G. (2002). Prevalence, expenditures, and complications of multiple chronic
conditions in the elderly. Arch Intern Med, 162(20), 2269-2276.
Wong, T. Y., Klein, R., Sun, C., Mitchell, P., Couper, D. J., Lai, H., et al. (2006). Age-related macular degeneration
and risk for stroke. Ann Intern Med, 145(2), 98-106.
Wong, T. Y., Tikellis, G., Sun, C., Klein, R., Couper, D. J., & Sharrett, A. R. (2007). Age-related macular
degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.
Ophthalmology, 114(1), 86-91.
Zhan, X., Larson, D. E., Wang, C., Koboldt, D. C., Sergeev, Y. V., Fulton, R. S., et al. (2013). Identification of a
rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet, 45(11),
1375-1379.
Zweifel, S. A., Imamura, Y., Spaide, T. C., Fujiwara, T., & Spaide, R. F. (2010). Prevalence and significance of
subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration.
Ophthalmology, 117(9), 1775-1781.

45

